172 related articles for article (PubMed ID: 1313259)
1. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
2. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
3. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
5. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
Sills T; Heptinstall S
Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
[TBL] [Abstract][Full Text] [Related]
6. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
Haslam RJ; Rosson GM
Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
[No Abstract] [Full Text] [Related]
7. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
8. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
O'Brien JR; Etherington MD; Salmon GP
Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
[No Abstract] [Full Text] [Related]
9. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
[No Abstract] [Full Text] [Related]
10. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
11. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
12. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
13. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Tanaka NG; Tohgo A; Ogawa H; Osada Y
Anticancer Res; 1986; 6(4):543-8. PubMed ID: 3019218
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet cyclic 3',5'-adenosine-monophosphate phosphodiesterases by pentifylline.
Stefanovich V
Arzneimittelforschung; 1975 May; 25(5):740-1. PubMed ID: 170944
[TBL] [Abstract][Full Text] [Related]
15. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Gillespie E
Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
[No Abstract] [Full Text] [Related]
17. Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
Tohgo A; Tanaka NG; Osada Y
Invasion Metastasis; 1990; 10(1):1-17. PubMed ID: 2154413
[TBL] [Abstract][Full Text] [Related]
18. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
19. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
